The aim of this study was to evaluate the influence of statins on the growth of small abdominal aortic aneurysms (AAAs).
Methods
We retrospectively examined AAA diameter in 211 patients who had undergone serial imaging surveillance.
Results
Patients treated with and without statins were similar regarding age, initial aneurysm size, diagnosis of diabetes and hypertension, and smoking history. Patients receiving statins had a decreased aneurysm growth rate compared with those patients not receiving statins (0.9 mm/y [interquartile range, −1.0 to +1.0] vs 3.2 mm/y [interquartile range, 2.0-4.9], P < 0.0001). This difference in the rate of growth was maintained after adjusting for potential confounding factors.
Conclusions
To date, this is the one of the largest retrospective studies demonstrating an association between statin use and decreased growth rate of AAA.
BengtssonH, BergqvistD, EkbergO. A population based screening of abdominal aortic aneurysms. Eur J Vasc Surg. 1991; 5: 53–57.
2.
ScottR.The Multicentre Aneurysm Screening Study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: a randomised controlled trial. Lancet. 2002; 360: 1531–1539.
3.
MorrisG, HubbardC, QuickC.An abdominal aortic aneurysm screening programme for all males over the age of 50 years. Eur J Vasc Surg. 1994; 8: 156–160.
4.
SimoniG, PastorinoC, PerroneR. Screening for abdominal aortic aneurysms and associated risk factors in a general population. Eur J Vasc Endovasc Surg. 1995; 10: 207–210.
5.
HallettJW.Management of abdominal aortic aneurysms. Mayo Clin Proc. 2000; 75: 395–399.
6.
LederleFA, JohnsonGR, WilsonSE. Prevalence and associations of abdominal aortic aneurysm detected through screening. Ann Intern Med. 1997; 126: 441.
7.
Participants UKSAT. Long-term outcomes of immediate repair compared with surveillance of small abdominal aortic aneurysms. N Engl J Med. 2002; 346: 1445–1452.
8.
StrachanD.Predictors of death from aortic aneurysm among middle aged men: the Whitehall study. Br J Surg. 1991; 78: 401–404.
9.
HoesA, Van UrkH, HofmanA. Aneurysms of the abdominal aorta in older adults: the Rotterdam study. Am J Epidemiol. 1995; 142: 1291–1299.
10.
AlcornHG, WolfsonSKJr, Sutton-TyrrellK. Risk factors for abdominal aortic aneurysms in older adults enrolled in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 1996; 16: 963.
11.
JamrozikK, NormanPE, SpencerCA. Screening for abdominal aortic aneurysm: lessons from a population-based study. Med J Aust. 2000; 173: 345–350.
12.
BlanchardJF, ArmenianHK, FriesenPP.Risk factors for abdominal aortic aneurysm: results of a case-control study. Am J Epidemiol. 2000; 151: 575.
13.
BradyAR, ThompsonSG, FowkesFGR. Abdominal aortic aneurysm expansion: risk factors and time intervals for surveillance. Circulation. 2004; 110: 16.
14.
GolledgeJ, MullerJ, DaughertyA. Abdominal aortic aneurysm: pathogenesis and implications for management. Arterioscler Thromb Vasc Biol. 2006; 26: 2605.
15.
CornuzJ, Sidoti PintoC, TevaearaiH. Risk factors for asymptomatic abdominal aortic aneurysm. Eur J Public Health. 2004; 14: 343.
16.
GolledgeJ, NormanPE.Atherosclerosis and abdominal aortic aneurysm: cause, response, or common risk factors?Arterioscler Thromb Vasc Biol. 2010; 30: 1075.
17.
HirschAT, HaskalZJ, HertzerNR. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease: a collaborative report. Circulation. 2006; 113: e463.
FreestoneT, TurnerRJ, CoadyA. Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol. 1995; 15: 1145–1151.
20.
ElmoreJR, KeisterBF, FranklinDP. Expression of matrix metalloproteinases and TIMPs in human abdominal aortic aneurysms. Ann Vasc Surg. 1998; 12: 221–228.
21.
GoodallS, CrowtherM, HemingwayDM. Ubiquitous elevation of matrix metalloproteinase-2 expression in the vasculature of patients with abdominal aneurysms. Circulation. 2001; 104: 304.
22.
McMillanWD, TamarinaNA, CipolloneM. Size matters: the relationship between MMP-9 expression and aortic diameter. Circulation. 1997; 96: 2228.
23.
PetersenE, GineitisA, WågbergF. Activity of matrix metalloproteinase-2 and -9 in abdominal aortic aneurysms. Relation to size and rupture. Eur J Vasc Endovasc Surg. 2000; 20: 457–461.
24.
LongoGM, BudaSJ, FiottaN. MMP-12 has a role in abdominal aortic aneurysms in mice. Surgery. 2005; 137: 457–462.
25.
SukhijaR, AronowWS, SandhuR. Mortality and size of abdominal aortic aneurysm at long-term follow-up of patients not treated surgically and treated with and without statins. Am J Cardiolfs. 2006; 97: 279–280.
26.
MillerFJJr, SharpWJ, FangX. Oxidative stress in human abdominal aortic aneurysms: a potential mediator of aneurysmal remodeling. Arterioscler Thromb Vasc Biol. 2002; 22: 560–565.
27.
RajagopalanS, MengXP, RamasamyS. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest. 1996; 98: 2572–2579.
28.
LiPF, DietzR, von HarsdorfR. Reactive oxygen species induce apoptosis of vascular smooth muscle cell. FEBS Lett. 1997; 404: 249–252.
29.
ZhangJ, SchmidtJ, RyschichE. Inducible nitric oxide synthase is present in human abdominal aortic aneurysm and promotes oxidative vascular injury. J Vasc Surg. 2003; 38: 360–367.
30.
XiongW, MactaggartJ, KnispelR. Inhibition of reactive oxygen species attenuates aneurysm formation in a murine model. Atherosclerosis. 2009; 202: 128–134.
NagashimaH, AokaY, SakomuraY. A 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, cerivastatin, suppresses production of matrix metalloproteinase-9 in human abdominal aortic aneurysm wall. J Vasc Surg. 2002; 36: 158–163.
35.
AikawaM, RabkinE, SugiyamaS. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation. 2001; 103: 276.
36.
ParaskevasKI, StathopoulosV, MikhailidisDP.Pleiotropic effects of statins: implications for a wide range of diseases. Curr Vasc Pharmacol. 2008; 6: 237–239.
SteinmetzEF, BuckleyC, ShamesML. Treatment with simvastatin suppresses the development of experimental abdominal aortic aneurysms in normal and hypercholesterolemic mice. Ann Surg. 2005; 241: 92.
39.
SaratzisA, KitasGD, SaratzisN. Can statins suppress the development of abdominal aortic aneurysms? A review of the current evidence. Angiology. 2010; 61: 137.
40.
ShirayaS, MiyakeT, AokiM. Inhibition of development of experimental aortic abdominal aneurysm in rat model by atorvastatin through inhibition of macrophage migration. Atherosclerosis. 2009; 202: 34–40.
41.
EvansJ, PowellJ, SchwalbeE. Simvastatin attenuates the activity of matrix metalloprotease-9 in aneurysmal aortic tissue. Eur J Vasc Endovasc Surg. 2007; 34: 302–303.
42.
TwineC, WilliamsI.Systematic review and meta analysis of the effects of statin therapy on abdominal aortic aneurysms. Br J Surg. 2011; 98: 346–353.
43.
SchoutenO, van LaanenJHH, BoersmaE. Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth. Eur J Vasc Endovasc Surg. 2006; 32: 21–26.
44.
KarlssonL, BergqvistD, LindbäckJ. Expansion of small-diameter abdominal aortic aneurysms is not reflected by the release of inflammatory mediators IL-6, MMP-9 and CRP in plasma. Eur J Vasc Endovasc Surg. 2009; 37: 420–424.
45.
MosorinM, NiemelaE, HeikkinenJ. The use of statins and fate of small abdominal aortic aneurysms. Interact Cardiovasc Thorac Surg. 2008; 7: 578–581.
46.
FergusonCD, ClancyP, BourkeB. Association of statin prescription with small abdominal aortic aneurysm progression. Am Heart J. 2010; 159: 307–313.
47.
SweetingMJ, ThompsonSG, BrownLC. Use of angiotensin converting enzyme inhibitors is associated with increased growth rate of abdominal aortic aneurysms. J Vasc Surg. 2010; 52: 1–4.
48.
ThompsonA, CooperJ, AshtonH. Growth rates of small abdominal aortic aneurysms correlate with clinical events. Br J Surg. 2010; 97: 37–44.
49.
TwineCP, WilliamsIM.Systematic review and meta-analysis of the effects of statin therapy on abdominal aortic aneurysms (Br J Surg 2011;98:362-353). Br J Surg. 2011; 98: 744–745.
50.
TakagiH, MatsuiM, UmemotoT.A meta-analysis of clinical studies of statins for prevention of abdominal aortic aneurysm expansion. J Vasc Surg. 2010; 52: 1675–1681.
51.
LederleFA, WilsonSE, JohnsonGR. Immediate repair compared with surveillance of small abdominal aortic aneurysms. N Engl J Med. 2002; 346: 1437–1444.
52.
GadowskiGR, PilcherDB, RicciMA.Abdominal aortic aneurysm expansion rate: effect of size and β-adrenergic blockade. J Vasc Surg. 1994; 19: 727–731.
53.
LeachS, TooleA, SternH. Effect of β-adrenergic blockade on the growth rate of abdominal aortic aneurysms. Arch Surg. 1988; 123: 606–609.
54.
LiaoS, MirallesM, KelleyBJ. Suppression of experimental abdominal aortic aneurysms in the rat by treatment with angiotensin-converting enzyme inhibitors. J Vasc Surg. 2001; 33: 1057–1064.
55.
TomitaN, YamasakiK, IzawaK. Inhibition of experimental abdominal aortic aneurysm progression by nifedipine. Int J Mol Med. 2008; 21: 239–244.
56.
HosokawaY.Effects of angiotensin receptor blocker and calcium channel blocker on experimental abdominal aortic aneurysms in a hamster model. Kurume Med J. 2010; 57: 1–8.
